Close menu




January 6th, 2021 | 07:57 CET

Amazon, dynaCERT, Pfizer: Innovation thanks to proven ideas

  • Investments
Photo credits: pixabay.com

Individual stocks in the stock market are valued based on future earnings potential, which results in high demand for companies poised for growth. The most recent examples are hydrogen stocks, such as NEL and Plug Power. Gold has also been experiencing a renaissance since the pandemic's outbreak and is poised to climb to new heights in the first trading days of 2021. However, good returns can also be achieved with supposedly established stocks. Although ordering from Amazon is as obvious to many of us as going to the nearest supermarket, the Company still has excellent growth potential.

time to read: 3 minutes | Author: Nico Popp
ISIN: CA26780A1084 , US0231351067 , US7170811035

Table of contents:


    Amazon: Growth at a high level

    Amazon has long been more than just a retailer on the web. In addition to ordering almost any product via the platform, Amazon also offers services and is a media company. With inexpensive tablets and the streaming offer Prime Video, the former bookseller has made it into many living rooms. In the meantime, even the Bundesliga soccer league is flickering across the in-house streaming platform. Traditional online retailing has become even more popular as a result of the pandemic. Many older people ventured online for the first time in March 2020, placed orders and had good experiences. Amazon, in particular, as the top dog with accommodating warranty processing, is likely to benefit from the growing popularity of older generations.

    While traditional retailers had to lay off staff and suffered from the pandemic restrictions, Amazon hired a whole 400,000 new people last year. This contrast emphasizes how well-positioned Amazon is. The numbers are right, too. In the third quarter of 2020 alone, Amazon made a profit of USD 6.3 billion. That's already the next record after the quarter before. The stock has gained more than 50% on a one-year horizon and is also already ambitiously valued. Amazon remains a stable value. Ten years from now, Amazon will still be making healthy sales - and it remains to be seen how many traditional retailers will fare by then.

    dynaCERT: Hydrogen Catalysts and Software for the Traffic Turnaround

    The Canadian Company dynaCERT is also reaching for the stars. Its goal is to make existing vehicle fleets more sustainable. To this end, dynaCERT has developed an electrolysis unit with hydrogen technology that can be used primarily in large diesel engines and is said to optimize combustion by up to 19%. In recent months, some US municipalities have stepped in and converted their public transport systems. Public authorities, in particular, are under pressure to pursue sustainable solutions while keeping costs down. Compared to buses with electric motors, the purchase of a HydraGEN retrofit unit can pay for itself within 12 months, according to the manufacturer.

    In addition to its catalysts, dynaCERT is also active in the field of telematics software. The aim is to measure savings and use the wealth of data to improve the environmental balance sheet further. Thanks to the savings documentation, fleet operators can receive credits in the form of CO2 certificates that are publicly traded. These CO2 certificates create a further incentive to use dynaCERT's solutions. In German trading, the share was able to stabilize just below EUR 0.40 and recently indicated breakouts several times. Speculative investors can add the stock to their watchlist.

    Pfizer: Blockbusters secure the dividend

    The Pfizer share also shows that share price gains and innovations do not necessarily have to come from startups with revolutionary technology. Although the pharmaceutical giant is cooperating with the Mainz-based Company BioNTech in producing the Covid-19 vaccine and is relying on the new mRNA technology, Pfizer also offers a lot of classic "bread-and-butter" business. In total, Pfizer has ten blockbuster drugs on offer, each of which generates more than USD 1 billion in sales. Pfizer has spun off its generics and consumer products business into a joint venture with GlaxoSmithKline and focuses only on high-margin drugs. In this way, Pfizer hopes to build on Viagra, Lipitor, and other former blockbusters' successes.

    This change in strategy has not yet gone down well on the stock market: Over a one-year period, the share price fell by 13.8% despite the vaccine hype. The value also shows a slight downward trend over a three-year period. However, Pfizer's dividend is the primary driver of returns: The Company recently announced its 328th consecutive quarterly dividend. The dividend yield is thus stable at over 4%. That is probably another reason why investor legend Warren Buffett has recently invested heavily in pharmaceutical stocks and has also bought Pfizer. Those who are not too bored by the leisurely share price development will find Pfizer a stable long-term pillar for their portfolio.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read